BostonGene highlights how its foundation models enable decision-making across drug development and clinical care, with growing adoption by leading biopharma partners WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene, developer of the leading AI foundation model for tumor and immune biology, today announced its participation at the 23rd Annual Meeting of the Japanese Society of Medical Oncology (JSMO2026) from March … [Read more…]

Additional Tranche D PDR1 bond financing from IPF for €3.75 million as part of the continuation plan validated by the Court of Economic Activities of Lyon. The Tranche D PDR bonds already issued and to be issued are simple bonds. LYON, France–(BUSINESS WIRE)–Regulatory News: POXEL SA (Euronext: POXEL – FR0012432516), a clinical-stage biopharmaceutical company that … [Read more…]

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the U.S. Food and Drug Administration (FDA) has approved Lifyorli™ (relacorilant) in combination with nab-paclitaxel for … [Read more…]

The Golden State Storm creates strategic alliance to bring cutting-edge, data-driven breathwork technology to women’s professional football, elevating athlete performance, recovery, and overall health OAKLAND, Calif.–(BUSINESS WIRE)–The Golden State Storm, the San Francisco Bay Area’s premier women’s professional tackle and flag football teams and member of the Women’s National Football Conference (WNFC) is proud to … [Read more…]

$49.1 million global net product revenue of EKTERLY® (sebetralstat) for the eight months ended December 31, 2025 1,702 patient start forms received in the US from launch through end of February, reflecting continued rapid adoption of first and only oral on-demand treatment for hereditary angioedema (HAE) EKTERLY launched in Japan by partner Kaken Pharmaceutical Co., … [Read more…]

WOODSTOCK, Ga.–(BUSINESS WIRE)–Prestige Medical Group, a physician-led healthcare organization serving North Georgia for more than 20 years, announced plans to open a new medical office in Woodstock, Georgia. The new location, opened on March 24, 2026, located at 102 Springfield Center Drive, Woodstock, GA 30188. The Woodstock office represents a strategic expansion of Prestige Medical … [Read more…]

Recognition highlights Anumana’s leadership in AI-driven cardiovascular detection and clinical decision support CAMBRIDGE, Mass.–(BUSINESS WIRE)–Anumana, a leader in AI-powered cardiovascular detection algorithms, today announced it has been named to Fast Company’s prestigious 2026 Most Innovative Companies list in the Medical Devices category. The annual award recognizes hardware and technologies changing how healthcare is delivered and … [Read more…]

− Efforts Aimed at Facilitating Earlier Diagnosis, Coordinated Care, and Long-Term Patient Impact in ATTR-CM – − Alnylam to Host TTR Investor Webinar Today at 9:30 am ET – CAMBRIDGE, Mass.–(BUSINESS WIRE)–Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced a set of strategic efforts designed to accelerate earlier recognition and improve … [Read more…]

First preclinical data on the Company’s lead program MOS101: a combination of ASTX295, a next-generation, clinical-stage MDM2 antagonist, and olaparib, an FDA-approved PARP inhibitor, in biomarker-selected solid tumors Additional data showcasing Mosaic’s Discovery Platform, PRIME, will be presented CAMBRIDGE, England–(BUSINESS WIRE)–Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) a clinical-stage oncology therapeutics company building the category … [Read more…]

— Acquisition Adds Clinical Stage Bispecific BCMAxCD3 T Cell Engager with Potential for Durable Immune Reset to Gilead’s Inflammation Portfolio — — Gilead Intends to Enter into a Strategic Collaboration with Galapagos on the Ouro Portfolio of Medicines — FOSTER CITY, Calif.–(BUSINESS WIRE)–#GILD–Gilead Sciences, Inc. (Nasdaq: GILD) announced today it has entered into a definitive … [Read more…]